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Summary Quantitative histology of bone changes, using undecalcified transiliac bone biopsies (UTBB), was
performed blindly in 46 individuals with monoclonal gammopathy (MG), including 17 with MG of
undetermined significance (MGUS) and 29 with overt multiple myeloma (MM). Three MGUS presented an
excess of osteoclastic resorption (OR) in the vicinity of clusters of tumour cells and developed overt B cell
malignancies, chronic lymphocytic leukaemia, Waldenstr6m's disease and MM respectively. On the other
hand, MGUS with normal OR remained stable (median follow-up=28 months), with one exception who
developed a systemic amyloidosis. In MM, excessive OR was only observed in areas invaded by myeloma
cells. OR was frequently normal in active MM lacking myeloma cells in UTBB. Active MM without lesions
on radiography had excessive OR. IgA and pure Bence Jones MM appeared more osteoclastic than IgG cases
(P<0.05). Ofmajor interest was the finding that one third of MM presented histological bone changes similar
to osteoporosis, osteosclerosis or osteoblastic metastasis. Two major findings must be emphasized from the
current data:
(i)
(ii)
UTBB could be of major interest for the early detection of a B cell malignancy;
heterogeneity of myeloma bone condition is unexpected. If some changes appear directly related to the
tumour (i.e. excessive OR or osteoblastic dysfunction), some others are probably accidentally associated
with it (i.e. osteoporosis), both needing treatment other than chemotherapy.
Lytic (osteoclastic) bone lesions (LBL) and hyper-
calcemia (HCa) are characteristic features of
multiple myeloma (MM) and are related to the
extent and severity of the disease (Durie & Salmon,
1975). Recent studies have shown that LBL were due
to osteoclast activating factor (OAF) production
by myeloma cells (Mundy et al., 1974; Gailani et al.,
1976). This is well supported by data from bone
biopsies showing that osteoclasts are present in
increased number in resorption lacunae, only in
bone lying adjacent to collections of myeloma cells
(Mundy et al., 1974; Valentin-Opran et al., 1982).
On the other hand, such LBL were not observed
in individuals with either a monoclonal gammopathy
of undetermined significance (MGUS) (Kyle, 1978)
or a smouldering myeloma (SMM) (Kyle & Greipp,
1980). However, some of the individuals with either
MGUS or SMM developed overt MM within a few
months or years (Kyle, 1978; Greipp & Kyle, 1983).
In these last patients, the presence of a low percent-
age of proliferating plasma cells in the bone marrow
was the earliest symptom of malignancy (Greipp &
Kyle, 1983; Boccadoro et al., 1984).
Since osteoclastic resorption (with LBL) is the
major feature of malignancy, and since bone radio-
graphy is often deficient at an early stage of the
disease, it was important to evaluate the help of
undecalcified transiliac bone biopsies (UTBB), in
patients with monoclonal gammopathy (MG), in
the differential diagnosis between benign and mal-
ignant MG, based on the early detection of an
abnormal osteoclastic resorption in the vicinity of
the small number of lymphoid and/or plasma cells
present in the bone marrow. Furthermore, if an
excess of osteoclastic resorption is a usual feature
of overt MM, other bone features were also de-
scribed, including osteoporosis, osteosclerosis and
osteomalacia. These last features are generally re-
cognized at the clinical and radiological levels,
when they are dominant presenting features or part
of a special entity such as the Crow-Fukase
(Nakanishi et al., 1984) or Fanconi (Maldonado et
al., 1975) syndromes. However, it would be of
major importance to detect such features at the
histological level, since effective drugs are presently
available to treat non malignant bone diseases.
We present the results of a prospective study of
bone changes in 46 individuals with MG. Our
current data show that UTBB could be a valuable
method to detect, at the histological level, an early
B cell malignancy in patients with *a so-called
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MGUS. Furthermore, our results clearly demon-
strate that bone conditions are very heterogeneous
in patients with overt MM and that these patients
could benefit by some specific treatments adjusted
to their bone condition.
For statistical analyses, the Wilcoxon test (i.e.
sum rank test), and the chi-square method with the
Yates correction as necessary, were used.
Results
Patients and methods
Undecalcified transiliac bone biopsies (UTBB) were
performed on 46 individuals with MG, including 17
cases with MGUS and 29 cases with overt MM.
Two patients with overt MM had 2 UTBB (at
diagnosis and during the plateau phase).
Patients with overt MM fulfilled the diagnostic
criteria of the Southwest Oncology Group of USA
(Durie & Salmon, 1977). Twenty-seven patients had
at least one lytic bone lesion (LBL) on radiography
and 2 had severe anaemia (haemoglobin 8.7 and
8.5 gdl-1, respectively) without LBL. There were
17IgG MM, 10IgA and 2 pure Bence Jones MM,
with a mean age of 66+9 years and a sex ratio
(M:F)=0.34. Sixty-five percent of biopsies were
performed at diagnosis. Five patients were hyper-
calcaemic at the time of biopsy (i.e. serum calcium
levels . 2.75mmol I-1).
Individuals with MGUS were asymptomatic (i.e.
no LBL, no anaemia, no hypercalcaemia and
normal renal function). Two out of these 17
MGUS fulfilled the diagnostic criteria of the
SWOG, one because of high levels of his mono-
clonal IgG lambda (3.24gdl- 1) and the second
because of the association of 13% of plasma cells
in his bone marrow, with intermediate levels of his
monoclonal IgG kappa (2.76gl-1) and low levels
of polyclonal IgA and IgM. The 15 remaining
individuals did not fulfil the diagnostic criteria of
the SWOG but 3 individuals with IgM MGUS
presented high IgM levels (respectively 1.8, 3.0 and
2.6gdl-'), compatible with a B cell malignancy.
Two of them had significant reduction of poly-
clonal IgG and IgA. None had detectable abnormal
lymphoid cells on bone marrow smears. The pre-
senting features of individuals with MGUS were as
follows: 11 IgG cases, 3IgA, 3 IgM, mean age
65+ 10 years and sex ratio M:F equal to 0.67.
Bone biopsies were performed, embedded and
blindly analysed as previously described by
Valentin-Opran (1982) and by ourselves (for
embedding) (Chappard et al., 1983). The following
parameters were defined as outlined in Table I:
trabecular bone volume (TBV), total trabecular
resorption surfaces (TTRS), relative osteoid volume
(OV), relative osteoid surface (OS) and thickness
index of osteoid seams (TOS). Results were com-
pared with those of age-matched normal control
subjects.
Analysis ofthe bone condition ofindividuals with a
monoclonal gammopathy ofundetermined
significance (MGUS)
The trabecular bone volume (TBV) was normal in
16 out 17 individuals with MGUS. One indi-
vidual with MGUS presented vertebral crushes re-
lated to a well-documented cortisonic osteoporosis
and with a significant reduction of his TBV: 7.88%,
less than the lowest limit of 2 standard deviations
(s.d.) below the mean value defined in age-sex
matched normal controls.
Table I Definitions used in the current work, according
to Valentin-Opran et al. (1982)
Trabecular bone volume (TBV):
Percentage of the space limited by subcortical envelopes
occupied by the trabeculae.
Total trabecular resorption surfaces (TTRS):
Percentage of the total trabecular surfaces where marks of
a previous resorption were visible, whether or not they
contained osteoclasts.
Relative osteoid volume (OV):
Percentage of the TBV occupied by osteoid.
Relative osteoid surface (OS):
Percentage of total trabecular bone surfaces covered with
osteoid seams.
Thickness index of osteoid seams (TOS):
OV/OS ratio.
The analyses of the total trabecular resorption
surfaces (TTRS) were of major interest. As previ-
ously described in 'Patients and methods' 2 indi-
viduals with an IgG MGUS presented a high risk
of malignancy because they fulfilled the diagnostic
criteria of MM. Bone marrow smears had shown
13% and 8% of atypical plasma cells. Three indi-
viduals with 1gM MGUS presented an intermediate
risk of malignancy (i.e. high IgM levels, polyclonal
suppression in 2 cases but no atypical cells in the
bone marrow). Twelve individuals presented the
lowest risk. In these last cases, no atypical lym-
phoid or plasma cells were observed on the bone
biopsies (UTBB) and the TTRS were strictly
normal. These MGUS remained stable (mean and
median follow-up time: 28 months). For the 2 IgG
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confirmed the presence of a small number of atyp-
ical plasma cells in both cases. One had a signifi-
cant increase of TTRS (6.3% more than the highest
limit of 2s.d. above the mean value). Excess of
osteoclastic resorption was observed in the vicinity
of plasma cells. This patient developed overt MM
with extensive lytic bone lesions (LBL) 28 months
later. In the second individual, TTRS were strictly
normal. A systemic amyloidosis was obvious in this
case 2 years later, without the LBL which would
suggest a true MM. In the subset of 3 IgM MGUS
with an intermediate risk, one individual had
normal TTRS and did not develop malignancy
(follow up=3 years). On the other hand, TTRS
were abnormal in the 2 other cases, 6.7% and
12.1% respectively. In the first case (i.e. 6.7%)
osteoclastic resorption was observed in the vicinity
of clusters of small lymphoid cells and a chronic
lymphocytic leukaemia developed within 1 year,
with a fulminant progression. In the second case,
the dramatic increase of osteoclastic resorption
(12.1%) was found in the vicinity of clusters of
lymphoplasmacytic cells, pointing to a diagnosis of
Waldenstrom's disease.
Analysis ofthe bone condition ofpatients with
multiple myeloma (MM)
We have included in this analysis 31 UTBB from
29 patients with overt MM and one UTBB from an
individual with MGUS with subsequent overt MM
(total=32 UTBB).
Trabecular bone volume (TBV) The analysis of
TBV in MM was summarized in Table II. The
distribution of TBV was found to be normal, with
a large majority of patients having normal TBV
(66%). However, a small percentage (16%) of
patients had a decrease of their TBV (<11%: ver-
tebral crush cut-off) including 3 women with a
significant reduction: mean age=76+4 years, mean
Table II Trabecular bone volumes (TBV) in patients
with multiple myeloma
Normal TBV 21/32 (66%)
TBV< 11%a 8/32
(a) Less than 11% but notb
significantly decreased 5/32
(b) Significantlyb decreased 3/32
Increase ofTBVb 3/32
(a) Increased osteoid bone 1/3
(b) Increased calcified bone 2/3
aVertebral crush cut-off.
bSignificant increase/decrease defined as more or less
than the upper/lower limit of 2 s.d. above/below the mean
value (age/sex matched normal controls).
TBV=6.5+ 1.9%. Their bone condition in terms of
TBV appeared identical to that of senile osteo-
porosis. Of major interest was the fact that the
opposite feature was also observed. Indeed, 3 cases
of MM had a significant increase of their TBV:
mean value=29.5+0.7%. In one case, this increase
involved the osteoid volume (OV), with a dramatic
increase up to 40.1% (normal OV
value=2.8+1.8%), in association with an increase
of osteoid surfaces, the thickness index of the
osteoid seams remaining normal. This histological
feature was identical to that of osteoblastic meta-
stasis. This patient however presented extensive
LBL and hypercalcaemia. In 2 other cases, the
increase involved the calcified bone, with an histo-
logical (but not radiological) feature of 'osteo-
sclerotic' MM (in spite of LBL on radiography).
These data have shown that MM, seemingly an
homogeneous pool of patients with LBL and some-
times (30%) hypercalcaemia, was in fact hetero-
geneous at the histological level, including features
similar to those of true osteoporosis, osteoblastic
metastasis or osteosclerosis.
Total trabecular resorption surfaces (TTRS) As
outlined in Table III, the percentage of TTRS was
closely dependent on the presence (or not) of
myeloma cells in the bone sample. A significant
increase of TTRS was observed in patients with an
intermediate or massive invasion of bone marrow
by myeloma cells in comparison with those without
invasion or presenting few myeloma cells in their
bone marrow: mean TTRS= 13.31 +3.72% vs.
4.67+1.73% (P<0.001). When myeloma cells were
lacking, the percentage of TTRS did not differ
significantly from that of normal individuals or
individuals with MGUS. As illustrated in Table III,
only 31% of patients with active MM had an
increase of TTRS when there was a lack, or a small
number, of myeloma cells in the sample. Of major
interest, osteoclastic resorption was significantly less
marked in IgG MM than in IgA and pure Bence
Jones MM (Table III, sections 3 and 4). Two
patients with stage III MM presented no LBL on
bone radiography. Both had a significant increase
of TTRS: 8.32 and 10.9% respectively. For the
overall patients with bone marrow invasion by
myeloma cells, no correlation wasfound between the
extent ofLBL and the TTRS.
Analysis ofosteoidparameters in individuals with
multiple myeloma
An increase of at least one osteoid parameter (i.e.
osteoid volume, osteoid surfaces or thickness index
of osteoid seams) was found on 20% of UTBB
from myeloma patients with significant bone mar-
row invasion as opposed to 68% of non invaded808 R. BATAILLE et al.
Table III Total trabecular resorption surfaces (TTRS)
according to the clinical condition (benign or malignant
monoclonal gammopathy) and bone marrow invasion by
myeloma cells
% Abnormal'
Bone clinical condition TTRS values
1. Monoclonal
gammopathy
of unknown significance
(MGUS) (n=14) 4.11+1.17 0%
2. Multiple myeloma
(MM)
with low or no plasma
cell invasion (n= 18) 4.70+ 1.78 16%
A. Indolent disease (5) 3.93+0.63 00%
B. Active disease (13) 4.99+2.00 31%
3. Multiple myeloma with
intermediate invasion
(n=8) 12.76+3.05 100%
A. IgG 10.37+0.42
B. IgA+Bence Jones 15.15+2.52
4. Multiple myeloma with
massive invasion
(n=5, all of G type) 14.20+4.85 100%
aDefined as the upper limit of 2 s.d. above the mean
values=5.8%.
(1) Three individuals (2 IgM and 1 IgG) with subsequent
B cell malignancy (2 cases) or probably B cell
malignancy at the time of biopsy (1 case) excluded.
(2) TTRS significantly less than that of 3. P<0.0005.
(3) TTRS for IgG significantly less than that of IgA.
P<0.05.
(4) One patient with dramatic osteoid volume increase
excluded (see Results).
biopsies (P<0.01). On the other hand, a decrease
of osteoid parameters, especially osteoid volume
was observed in 36% of invaded bone marrows. As
previously described above), the most dramatic
change in osteoid volume was observed in an IgA
MM presenting a tremendous increase of osteoid
volume (40.1% vs. 2.8+1.8% for normal value),
in association with an increase of TBV and OS, the
TOS remaining normal.
Discussion
We have blindly quantified bone changes, using
undecalcified transiliac bone biopsies (UTBB), in 46
individuals with monoclonal gammopathy (MG),
including 17 with MG of undetermined significance
(MGUS) and 29 with overt multiple myeloma
(MM). Two findings appeared of interest for the
diagnosis and the management of B cell malignancy
in general, and of MM:
(i) the predictive value of an excess of osteoclastic
resorption (OR) for the early detection of a B
cell malignancy;
(ii) the presence in some MM of particular features
of osteoporosis, osteosclerosis or features iden-
tical to those of osteoblastic metastasis, sug-
gesting an unexpected heterogeneity of the bone
condition ofmyeloma patients.
In 5 individuals with MGUS, at risk to the emer-
gence of a B cell malignancy, an excessive OR was
observed in 3 cases in the vicinity. of lymphoid or
lymphoplasma cells. One patient had
Waldenstr6m's disease at the time of biopsy, the
others developed respectively a chronic lymphocytic
leukaemia and an MM. When OR was normal, no
B cell malignancy was observed after a mean/
median follow-up of 28 months. Individuals with
MGUS or smouldering myeloma (SMM) are at
greater risk of B cell malignancy including MM
(Kyle, 1978; Greipp & Kyle, 1983). In this group of
MG, the presence of a low percentage of proliferat-
ing plasma cells in the bone marrow is the earliest
symptom of malignancy (Greipp & Kyle, 1983;
Boccadoro et al., 1984). Although our results are
preliminary, they indicate that UTBB could be
another tool to detect early malignant clones and
also suggest that excessive OR is probably frequent
in B cell malignancies other than MM in spite of
the fact that LBL on radiography and hyper-
calcaemia were rather uncommon (<3% of cases)
(Canellos, 1974). Recently we have shown that
some unusual B cell cancers could produce signi-
ficant amounts of osteoclast activating factors and
mimic MM (Rossi & Bataille, 1985). LBL and
hypercalcaemia are common features of MM and
the consequence of an excessive OR. However, no
correlation was found between the extent of LBL-
and the level of OR in this study. Two stage III
MM without LBL on radiography had a significant
excess of OR. These data suggest that the large
majority of myeloma clones produce local osteo-
clast activating factors, even when LBL are not
obvious on radiography. The fact that excessive OR
was observed only in the vicinity of tumour cells
suggests the production of local factors only by
tumour cells. A normal OR was observed in UTBB
lacking myeloma cells, even from patients with
active MM. The fact that IgA MM were found to
be more osteoclastic concurs with previous data
showing a more aggressive bone disease in these
patients (Durie et al., 1981), and their higher sensi-
tivity to antiosteoclastic drugs (Bataille & Sany,
1982). This could be explained by a higher pro-
duction of osteoclastic factors, as emphasized by
Durie et al. (1981). Similar observations were made
by ourselves (Rossi & Bataille 1984; and unpub-
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was another interesting parameter of active OR
(Valentin-Opran et al., 1982). In our experience, the
reliability of this parameter was not good and was
abandoned. However, the osteoclast count and the
evaluation of their activity could be significantly
improved using osteoclast acid phosphatase staining
as previously described by us (Chappard et al.,
1983).
If excessive OR was a common feature of MM
regardless of the presence and extent of LBL on
radiography, some particular features were seen in
certain patients. A dramatic decrease of the TBV
was observed in 3 elderly women with MM (10%
of cases). This osteoporosis could be related to MM
or could be a true senile osteoporosis associated
with MM. The fact that the distribution of TBV in
our population of MM was normal and that 2 of
these patients did not have any myeloma cells in
their UTBB would indicate an osteoporosis acci-
dentally associated with haematological disease (see
below), leading to therapy other than chemo-
therapy. In spite of the fact that sodium fluoride,
calcium and vitamin D did not improve a large
population of MM (Cohen et al., 1984), this special
subset of patients could take advantage of this type
of specific treatment, perhaps alternating with anti-
osteoclastic drugs such as diphosphonates, already
proven useful in MM (Delmas et al., 1982; Radl et
al., 1985). The opposite feature (i.e. significant
increase of TBV) was observed in a similar per-
centage of patients (3 cases, 10%) with active MM,
LBL on radiography and myeloma cells in the
biopsy (2 cases). In 2 cases, this increase was a real
increase of the calcified bone volume. At the histo-
logical level, these case could be described as osteo-
sclerotic MM whereas this entity turns out to be
exceptional at the radiological level. The third
patient had in fact an increase of the osteoid
volume without osteomalacia since the thickness
index of the osteoid seams was normal. TTRS were
normal in spite of extensive LBL and hyper-
calcaemia. This feature, unusual in MM, was more
common in osteoblastic metastasis and could sug-
gest that rare myeloma clones behave like these
metastatic tumours on account of the action of
special soluble factors.
The fact that the TBV was not significantly
decreased in about 90% of myeloma patients is of
major interest. Indeed, osteoporosis (i.e. post-meno-
pausal or senile) and MGUS are common after 60
years of age. The probability for an individual to
have both is greater than to have true overt MM.
This association of common osteoporosis (with
radiological features) and MGUS was previously
discussed by Buonomore et al. (1970) and later by
Maldonado et al. (1975) in terms of 'pseudo-
myeloma'. Our data emphasize another possibility,
i.e. a true senile osteoporosis associated with overt
MM and not simply MGUS. In such a difficult
problem, we suggest that the evaluation of both the
TBV and the TTRS could be very useful in discrim-
inating between the several possibilities, keeping in
mind that: (a) a low trabecular bone volume
favours osteoporosis and (b) an excessive osteo-
clastic resorption in the vicinity of plasma cells
favours malignancy.
The analysis of osteoid parameters was more
complex, especially because the evaluation of the
trabecular calcification rate was not available in
our study. With one exception, previously empha-
sized, an increase of osteoid parameters was more
frequently observed in non-invaded areas with the
opposite features in invaded areas. These data
concur with those of Valentin-Opran (1982). The
explanation given by Valentin-Opran remains satis-
factory, with the exception of rare myeloma clones
with both high osteoclastic and osteoblastic activity
(one patient in this study), suggesting that osteo-
blasts were scant and inactive in invaded areas,
more numerous but slowly active in less invaded
areas. In both cases, at the cell level, the suppres-
sion of osteoblastic activity could be mediated by
osteoclast activating factors themselves, able to in-
hibit collagen synthesis in vitro (Raisz et al., 1975),
or by other soluble factors. This low osteoblastic
activity in the vicinity of tumour sites could ac-
count for the poor value of bone scintigraphy in
MM, illustrated by a lack of radioactive molecule
uptake in about 50% of myeloma bone lesions
(Woolfenden et al., 1980; Bataille et al., 1982).
Our present study is the second on the quanti-
tative histology of bone changes in patients with
MM (Valentin-Opran et al., 1982) and the first on
patients with MGUS. Taken together, these two
studies demonstrate that quantitative histology is
necessary in patients with MG, the information
given by this method being complementary to that
of bone marrow smears and bone marrow biopsies.
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